Cancer stem cells (CSCs) are responsible for tumor initiation, progression, and resistance to therapeutic agents; they are usually less sensitive to conventional cancer therapies, and could cause tumor relapse. An ideal therapeutic strategy would therefore be to selectively target and destroy CSCs, thereby preventing tumor relapse. The aim of the present study was to evaluate the effectiveness of dendritic cells (DCs) pulsed with antigen derived from CD105+ human renal cell carcinoma (RCC) CSCs against renal cancer cells in vitro and in vivo. We identified stem-like characteristics of CD105+ cells in two human RCC cell lines: A498 and SK-RC-39. Loading with cell lysates did not change the characteristics of the DCs. However, DCs loaded with lysates derived from CD105+ CSCs induced more functionally specific active T cells and specific antibodies against CSCs, and clearly depressed the tumor growth in mice. Our results could form the basis for a novel strategy to improve the efficacy of DC-based immunotherapy for human RCC.
基金：
Guangdong Science and Technology Program [2013B021800063]; Guangdong Province Science and Technology Plan Project [2012A030400059]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81402560, 81472387]; Gillson Longenbaugh Foundation
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2017]版：
大类|2 区医学
小类|2 区生化与分子生物学2 区肿瘤学
最新[2023]版：
大类|2 区医学
小类|2 区生化与分子生物学3 区肿瘤学
第一作者：
第一作者机构：[1]Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol Southern China, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China;[2]Sun Yat Sen Univ, Dept Biotherapy, Ctr Canc, Guangzhou, Guangdong, Peoples R China;
通讯作者：
通讯机构：[1]Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol Southern China, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China;[2]Sun Yat Sen Univ, Dept Biotherapy, Ctr Canc, Guangzhou, Guangdong, Peoples R China;[3]Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA;
推荐引用方式(GB/T 7714)：
Zhang Xiao-Fei,Weng De-sheng,Pan Ke,et al.Dendritic-cell-based immunotherapy evokes potent anti-tumor immune responses in CD105+human renal cancer stem cells[J].MOLECULAR CARCINOGENESIS.2017,56(11):2499-2511.doi:10.1002/mc.22697.
APA：
Zhang, Xiao-Fei,Weng, De-sheng,Pan, Ke,Zhou, Zi-Qi,Pan, Qiu-zhong...&Xia, Jian-Chuan.(2017).Dendritic-cell-based immunotherapy evokes potent anti-tumor immune responses in CD105+human renal cancer stem cells.MOLECULAR CARCINOGENESIS,56,(11)
MLA：
Zhang, Xiao-Fei,et al."Dendritic-cell-based immunotherapy evokes potent anti-tumor immune responses in CD105+human renal cancer stem cells".MOLECULAR CARCINOGENESIS 56..11(2017):2499-2511
